Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06427330
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2024-05-10
Brief Title:
Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
Sponsor:
Institute of Hematology Blood Diseases Hospital China
Organization:
Institute of Hematology Blood Diseases Hospital China
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-05-20
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-05-20
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-05-20
Completion Date Type:
ESTIMATED
First Submit Date:
2024-05-10
First Submit QC Date:
May 21 2024
Study First Post Date:
2024-05-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-28
Last Update Post Date:
2024-05-23
Last Update Post Date Type:
ACTUAL